The anti-CTLA4 agent ipilimumab was explored in a phase I study on 12 R/R AML patients post ASCT; it allowed a complete response lasting greater than one year in five cases, despite reported immune-mediated toxic effects and graft versus host disease (GVHD) [120]. The gene discussed is CTLA4; the disease is acute myeloid leukemia.